Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 5/20 | 0.43 |
| ▸ | THRB | P10828 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | LPL | P06858 | 3/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31003471 | 0.80 | CDK1 (0.51) | CDK1KAT8PPARALPLLIPG | |
| SCHEMBL11806384 | 0.80 | CDK1 (0.51) | CDK1KAT8PPARALPLLIPG | |
| SCHEMBL10803882 | 0.78 | CDK1 (0.63) | CDK1KAT8PPARALPLLIPG | |
| SCHEMBL28823310 | 0.78 | CDK1 (0.63) | CDK1KAT8PPARALPLLIPG | |
| SCHEMBL29189689 | 0.78 | CDK1 (0.63) | CDK1KAT8PPARALPLLIPG | |
| SCHEMBL28970004 | 0.78 | CDK1 (0.63) | CDK1KAT8PPARALPLLIPG | |
| SCHEMBL8756317 | 0.78 | CDK1 (0.49) | CDK1KAT8PPARALPLLIPG | |
| SCHEMBL12641406 | 0.78 | TAAR1 (0.39) | CDK1 | |
| SCHEMBL1527136 | 0.76 | CDK1 (0.60) | CDK1KAT8PPARALPLLIPG | |
| SCHEMBL18850328 | 0.76 | SKP2 (0.53) | KAT8PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858617-B2 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | NORGINE B.V. (NL) | 2010-12-28 | — | — | US | disclosed |
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | LPL, LIPE, PNLIP | CDK1 2721/4885THRA 1232/4885THRB 1105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.